Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
177Lu-DOTA-EB-FAPI in End-stage Solid Tumors
NCT05963386Phase 2Completed
- Sponsor
- First Affiliated Hospital of Xiamen University
- Start
- Feb 2022
- Primary completion
- Sep 2024
- Modality
- Radiopharmaceutical
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of 177Lu-DOTA-EB-FAPI in solid tumor, sponsored by First Affiliated Hospital of Xiamen University. Primary endpoint: Radiological response (according to RECIST criteria) up to 6 months. Started Feb 2022; status: completed.
02
Drugs
177Lu-DOTA-EB-FAPI
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05963386.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05963386.